-
Crizotinib, sold
under the
brand name
Xalkori among others, is an anti-cancer
medication used for the
treatment of non-small cell lung
carcinoma (NSCLC)...
-
implications on the
response of the
tumour and
prognosis of the patient.
Crizotinib (also a ROS1 and c-MET inhibitor) was
approved in Aug 2011 by the US FDA...
-
positive non-small cell lung cancer.
Treatment with
crizotinib achieves 60%
response rate. However,
crizotinib showed no
improvement on
overall survival compared...
-
include velpatasvir/sofosbuvir, sofosbuvir/daclatasvir, osimertinib,
crizotinib, daclatasvir, sofosbuvir, afatinib, axitinib, brigatinib, baricitinib...
-
treatment of
adults with ALK‑positive
advanced NSCLC previously treated with
crizotinib. In the
United States, it is
indicated for the
treatment of
people with...
- been increasing. Recently, the
small molecule tyrosine kinase inhibitor,
crizotinib, was
approved for the
treatment of
patients with
metastatic NSCLC whose...
-
responses to
crizotinib while 1
patient previously treated with a corticosteroid, prednisone,
continued to have
progressive disease on
crizotinib; and 3) 6...
- patients.
Crizotinib,
which gained FDA
approval in
August 2011, is an
inhibitor of
several kinases,
specifically ALK, ROS1, and MET.
Crizotinib has been...
- Previously, it was only
indicated for
patients who had
developed resistant to
crizotinib,
another ALK inhibitor, but has
since had its
usage expanded to serve...
- in
hyperactive ALK protein,
which can be
treated with ALK
inhibitors crizotinib, or its
successors alectinib, brigatinib, and ceritinib.
Those treated...
